Treatment schema. Melphalan (MEL) was administered at a dose of 200 mg/m2 IV 2 days before the autograft using peripheral blood stem cells. Upon recovery from high-dose MEL, between 40 and 180 days after the autograft, patients proceeded to the nonmyeloablative allograft. The preparative regimen for the allograft consisted of total body irradiation (TBI) at 2 Gy on the day of transplant (HCT). Recipients of unrelated grafts were also given fludarabine (FLU) 30 mg/m2 on 3 consecutive days. Administration of cyclosporine (CSP) began at 5.0 mg/kg orally twice daily on days −3 through +100 (or +56 if related donor), and doses were then tapered to day 180. Mycophenolate mofetil (MMF) was given 15 mg/kg orally thrice daily until day +27 and twice daily thereafter only for unrelated donor recipients, with tapering of doses beginning on day +40 and treatment scheduled to end on day +96. Recipients of grafts from related donors received MMF at 15 mg/kg orally twice daily until day +27.
